Just four months after Paris-based ValiCene SA and Newtown, Pa.-based Kimeragen Inc. agreed to merge, the newly formed ValiGen has raised S25 million in a private placement. The funds will be used in the development of the company's genomics, bioinformatics and gene repair Technologies, as well as for administrative …
Комментариев нет:
Отправить комментарий